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N-acetylated α-linked acidic dipeptidase; NK = natural killer; NPY = neuropeptide Y; OA = osteoarthritis; PB = peripheral blood; QPP = quiescent
cell proline dipeptidase; RA = rheumatiod arthritis; RANTES = regulated upon activation normal T-cell expressed and secreted; SDF = stromal cell-
derived factor; SF = synovial fluid; SLE = systemic lupus erythematosus; SP = substance P; TGF = transforming growth factor; TNF = tumor necro-
sis factor; VIP = vasoactive intestinal peptide.
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Abstract
Several of the proinflammatory peptides involved in rheumatoid
arthritis pathogenesis, including peptides induced downstream of
tumor necrosis factor-α as well as the monocyte/T cell-attracting
chemokines RANTES and stromal cell-derived factor (SDF)-1α and
the neuropeptides vasoactive intestinal peptide (VIP) and
substance P, have their biological half-lives controlled by dipeptidyl
peptidase IV (DPPIV). Proteolysis by DPPIV regulates not only the
half-life but also receptor preference and downstream signaling. In
this article, we examine the role of DPPIV homologs, including
CD26, the canonical DPPIV, and their substrates in the
pathogenesis of rheumatoid arthritis. The differing specific
activities of the DPPIV family members and their differential
inhibitor response provide new insights into therapeutic design.
Introduction
A significant proportion of the biologically active peptides,
including systemic and locally acting neuropeptides, lympho-
kines, cytokines and chemokines, contain an evolutionarily
conserved amino-terminal penultimate proline residue as a
proteolytic-processing regulatory element. This penultimate
proline protects the peptide from general aminopeptidase
activity, which has led to the view that the high specificity of
the dipeptidyl aminopeptidases constitutes a critical
regulatory ‘check-point’ [1]. Limited proteolysis of such
peptides by dipeptidyl peptidase (DPP) IV and/or structural
homolog (DASH)-related molecules may lead to both
quantitative and, due to the diversification of their receptor
preference, qualitative changes to their signaling potentials
[2,3]. Molecules of the DASH family have been invoked in the
pathogenesis of a range of autoimmune processes, including
systemic lupus erythematosus (SLE) and multiple sclerosis, in
particular [4]. As these proteases and their substrates play a
fundamental role in the migration and activation of immune
cells and their interactions with extracellular matrix, we
examine here their likely role in the progression of rheumatoid
arthritis (RA).
It is tempting, although unrealistic, to propose that the
marked changes in DPPIV enzymatic activity in blood plasma,
synovial fluid (SF) and immune cells observed during the
course of RA might be causally related to the disease
etiology. Nevertheless, it is not presumptuous to propose that
once DPPIV levels are altered they would participate in a
positive-feedback cycle that could rapidly accelerate to
exacerbate damage and thus take part in RA pathogenesis.
Although this leads to speculation of therapeutic modalities
based upon inhibition of DPPIV enzymatic activity, gene
knockout experiments suggest that DASH family members
can to some extent compensate, but not fully substitute, for
each other [2,5]. As a consequence, inhibition of DPPIV
activity must be examined from the perspective of the
enzymatic activities and interactions of all DASH family
members rather than the functionality expressed by a single
enzyme in an isolated biochemical framework.
The members of the DASH family
Initially, DPPIV activity was classified simply by the enzymatic
reaction, cleavage of a dipeptide from the accessible amino
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terminus of proteins in which the second amino acid is a
proline (EC 3.4.14.5). Its expression was high on endothelial
cell membranes and also in tissues with strong secretory
capacity, including ovary, pancreas, liver and particularly
kidney where DPPIV constituted up to 14% of the total
membrane protein. In these tissues, the DPPIV levels were
constant and synthesis was believed to be constitutive. The
field took a vast leap forward when it was established that a
105 to 110 kDa membrane-expressed human lymphocyte
activation antigen, defined by the CD26 monoclonal antibody
cluster, was identical to DPPIV and was subject to activation-
induced regulation (for a review see [4]). This was rapidly
followed by the discovery that CD26 is itself the high affinity
lymphocyte adenosine deaminase (ADA)-binding protein.
Because the anti-folate treatments for RA, exemplified by
methotrexate, mediate their anti-inflammatory effects in part
through locally increasing extracellular adenosine concentra-
tions, the localization and functional activity of an adenosine-
metabolizing protein on activated T lymphocytes would
clearly be an undesirable state in RA [6-8].
Although the greatest part of systemic DPPIV activity resides
in both membrane-bound and, to some degree, proteolytically
cleaved soluble CD26, a significant amount of DPPIV activity
can be attributed to a growing panel of other proteins,
including fibroblast-activation protein α (FAP-α)/seprase,
quiescent cell proline dipeptidase (QPP), DPP8, DPP9,
attractin, N-acetylated α-linked acidic dipeptidases
(NAALADases) and thymus-specific serine protease [9].
These proteins form the DASH group on the basis of having
an associated DPPIV enzymatic activity with or without much
structural homology, or being structurally similar but
enzymatically inactive (DPP6, DPP10). In some instances, the
DPPIV activity is clearly intrinsic whereas in others the nature
of the DPPIV activity remains debatable. In these latter cases,
DPPIV activity may represent association with minimal
amounts of CD26, which results in enhanced substrate
hydrolysis, or may represent a separate enzyme specificity
that can also accept DPPIV substrates. The contamination
issue has been extensively examined and, to date, in the case
of attractin for example, there is no evidence of contamination
of purified preparations by CD26 [10,11]. This, however,
does not exclude association with other family members. The
possibility of alternative specificity is exemplified by the
NAALADases, where the primary function appears to be
glutamate carboxypeptidase II activity rather than
aminodipeptidase functionality. Alternatively, the FAP-
α/seprase protein exhibits both DPPIV and gelatinase
activity; this latter property has profound effects upon the
invasive properties of the expressing cell [2].
Most DPPIV/CD26 activity is membrane-expressed. There is,
however, a strong circulating activity, which may be of critical
importance for systemic bioactive peptide activity. Although
debate remains as to the relative contributions of cleaved
membrane CD26, attractin and secreted QPP to the soluble
circulating DPPIV-like enzymatic activity, the functional
consequences will be identical. Accordingly, this may provide
a mechanism for restricting activity of paracrine/autocrine
bioactive peptides at the site of release, and may further
ensure rapid down-regulation of physiologically activated
peptides such as glucagon-like peptide (GLP)-1, which is
released by the intestine but targets the pancreas. In
inflammatory reactions, it may provide a mechanism for
restricting chemokine-responding T cells to the inflamed
region. For example, both RANTES (regulated upon activation
normal T-cell expressed and secreted) and stromal cell-
derived factor (SDF)-1α are already known to be regulated by
DPPIV [12,13].
The DPPIV activity, gelatinase activity and ADA complex
forming function are differentially represented within individual
DASH proteins. In fact, some proteins such as DPP10 have
clear structural homology but no DPPIV activity at all. They
may retain some of the other activities, which include
association with the hematopoietic-specific CD45RO
tyrosine phosphatase, or interaction with collagen. In contrast
to human DPPIV/CD26, the mouse enzyme has no ADA
complex forming ability and is a marker of thymic
differentiation but is not an activation antigen. Nevertheless,
its membrane presence has profound influence over the
signal transduction responses of the T cell. This cautions
against extending too far CD26-related immune results in
mice to conclusions concerning RA pathogenesis and
therapy in humans.
DASH molecules in rheumatoid arthritis
Based upon the enzymatic activities of the DASH enzymes
described above, it is immediately apparent that DPPIV-like
and gelatinase activities, collagen binding and regulation of
extracellular adenosine could all have substantial roles in
every phase of an inflammatory response, from recognition
and proliferation to cytokine/chemokine activity and chemo-
taxis. It is from this vantage point that we will now view RA as
a chronic systemic inflammatory disease affecting mostly
articular tissues. RA may be initiated by an unknown antigenic
peptide derived either from an exogenous antigen or an
autoantigen. Presentation of a putative arthritogenic peptide
by RA-associated HLA-DRB1*0404 or HLA-DRB1*0401
results in release of IL-2 by CD4+ T cells and induction of
clonal expansion of other CD4+ T cells [14]. Cytokine and
growth factor release by the induced T cells stimulates B
cells, synoviocytes, and monocytes/macrophages, which leads
to enhanced leukocyte recruitment into the joint and synovitis.
The synovial inflammation results in release of matrix
metalloproteases and cysteine proteases, leading to
proteolytic degradation of the connective tissue [15,16].
Each of these processes will be affected by the presence of
DPPIV, not directly but, rather, indirectly through the
enzymatic processing of the bioactive peptides that regulate
each stage. Reflecting this, the use of new specific DPPIV
inhibitors to block RA and SLE development has led in the255
past year to three issued patents and eight pending
applications in the United States alone.
Dipeptidyl peptidase IV (CD26)
Although DPPIV activity is a generic term for the enzyme’s
catalytic functions, and may reside in several proteins, the use
of DPPIV as a protein descriptor has become synonymous
with CD26. As described above, the merging of the three
separate research directions involving cell surface DPPIV
activity, immune cell CD26 signal transduction, and ADA-
complex forming activity into studies of the multifunctional
CD26 have led to a more profound understanding of
inflammation. Specifically, modulation of CD26 activity will
affect chemotaxis, invasiveness, signal transduction, prolifer-
ation and recruitment of other immune cells; clearly, the
interaction of these activities will be well orchestrated in vivo
but unlikely to be recapitulated in assays in vitro.
CD26 is predominantly a type 2 integral plasma membrane
molecule expressed as a homodimer or heterodimer with
seprase, with or without bound ADA. A small proportion
appears to circulate in the plasma, cleaved from membrane
CD26 by an unknown mechanism, but at a site in the
membrane proximal extracellular domain. This cleavage is
intriguing because CD26 is relatively resistant to proteolytic
cleavage. CD26 is well represented in kidney, liver, pancreas
and ovary, on endothelial cells and is localized in secretory
vesicles destined for plasma membrane fusion in synovial
fibroblasts [17]. In cultured kidney cells, CD26 appears to
cycle from the membrane through early and late endosomes
back to the membrane and, through its DPPIV activity, is often
used as a marker of secretory vesicle traffic [18]. The low
secretory activity of resting T cells correlates well with the low
CD26 surface expression and the rapid upregulation and
sustained signal following activation supports a role for CD26
in maintaining and regulating stimulation. Although cross-
linking of CD26 with CD3 leads to increased activation and
proliferation, this cannot be a direct signal-transducing
property of CD26 as its cytoplasmic tail consists of only six
amino acids. This has led to the suggestion that CD26 directly
associates with the memory T cell marker CD45RO to
influence signaling. As intracellular CD26 moving in vesicles
to the plasma membrane is localized within the cholesterol/
sphingomyelin-rich lipid raft domains [19], it is likely that
associating with CD26 will help recruit signaling
costimulatory/regulatory molecules to the raft-localized T cell
receptor. In support of a more general function during
activation not restricted to T cells, CD26 is also found on
activated B cells, activated natural killer (NK) cells [20,21] and
some subpopulations of macrophages [22], where it plays a
role in regulation of maturation and migration of NK and NKT
cells, cytokine secretion, T cell-dependent antibody
production and immunoglobulin isotype switching of B cells
[5]. Reflecting this general upregulation and function in active
immune processes, the number of circulating CD26 positive
cells is higher in the active phases of autoimmune diseases
but decreased in immunosuppressions of varying origin
[23,24]. The ability of T cells to regulate their membrane levels
of CD26 is in sharp contrast to expression on endothelial and
renal cells, where CD26 is constitutively produced and
membrane levels are relatively constant. This suggests that
location may be critical and that locally situated peptides may
be exposed and vulnerable to T cell-expressed DPPIV.
The source and regulation of soluble DPPIV is more difficult
to ascertain. The possibility that secreted DPPIV may be
important in regulating T cell reactivity is provided by the
report that T cells from individuals with high serum DPPIV
levels are refractory to costimulatory enhancement by
exogenously added CD26 during response to tetanus toxoid
[25]. This effect may occur through modulation of adhesion-
or peptide-mediated costimulatory signaling since direct
stimulation through the T cell receptor is unaffected. Soluble
DPPIV stimulates proliferation of blood T cells induced by
recall antigens indirectly via antigen presenting cells [26] and
potentiates transendothelial migration of T cells [27], both
effects being dependent on intrinsic hydrolytic activity of the
enzyme. In general, lower DPPIV serum activity is associated
with immunosuppression, pregnancy, several kinds of cancer,
human immunodeficiency virus infection, and also with SLE
and irradiation [9,28-30]. In contrast, an increase of serum
DPPIV activity, together with an increased number of CD26
positive circulating cells, was observed during the rejection of
allografts [31].
In RA, decreased DPPIV enzymatic activity was observed in
blood plasma/sera compared with healthy controls [32].
Further studies demonstrated a significant inverse correlation
of serum DPPIV activity with disease severity as determined
by C-reactive protein concentration, the number of swollen
joints and with the Disease Activity Score 28 [33-35].
Hypersialylation is associated with a decrease in the specific
circulating DPPIV activity in RA patients, and the activity
could be restored following neuraminidase treatment [36].
The same study demonstrated that serum DPPIV from SLE
patients was also hypersialylated but activity was not restored
following neuraminidase treatment, from which it may be
inferred that differential post-translational glycosylation may
affect enzyme activity and/or substrate preference. A single
report notes no difference in DPPIV activity in the sera of RA
patients compared to the normal controls, but the study
groups in this report were not delineated by disease severity,
type of therapy or active/inactive disease states [37].
The relationship of serum DPPIV activity to clinical severity is
usually based on enzyme activity, which provides no
information on relative contributions of individual DASH family
members. Furthermore, the mechanism by which DPPIV
activity is reduced in the blood of RA patients remains purely
speculative at present. One possibility is that T cell activation
down-regulates the as yet unidentified protease that cleaves
and releases membrane CD26. Alterations in specific activity
Available online http://arthritis-research.com/content/7/6/253256
due to increases in other less active DASH forms may also
account for apparent reduced serum activity. Indeed, we have
observed patient-specific patterns of multiple molecular weight
forms bearing DPPIV-like activity in human plasma [35].
DPPIV/CD26 is strongly upregulated on peripheral blood (PB)
T cells of RA patients, where both the staining intensity and
number of positive cells correlate with disease activity
(Table 1). Despite reports that DPPIV/CD26 may be seen as a
Th1 response marker [33,38,39] based on cytokine release
following T cell receptor stimulation, this is arbitrary. First,
antibody ligation of the T cell receptor is not physiological, and
second, the delineation of human lymphocytes into Th1 and
Th2 subsets is considerably less precise than that of the
mouse. The consequences upon CD26 of activation by
lymphokines and cytokines are, however, specific and depend
upon the cell type responding. In T cells, CD26 is upregulated
by IL-12 and IL-2 but not by tumor necrosis factor (TNF)-α,
IFN-γ, IL-15 and IL-4, while TNF-α and IL-15 are efficient
stimulators of CD26 expression on NK cells and fibroblasts
[33,40-42]. Moreover, TNF-α neutralizing antibodies caused
down-regulation of CD26 expression in T cells [39].
The concentrations of IL-12 and IL-15 in sera of RA patients
are increased independently of disease activity, while blood
plasma DPPIV activity correlates inversely and T-cell DPPIV
activity/CD26 expression correlates positively with disease
severity. This serves only to confirm that regulation of surface
CD26 expression and secreted DPPIV activity is dependent
upon more than activation by a single stimulus, representing
rather the threshold response to a number of inputs. Although
it may seem counterintuitive to have an increase in circulating
activated T cell surface DPPIV activity while free soluble
enzyme is reduced in the plasma, this may be a simple
partitioning effect reflecting reduced proteolytic release of the
membrane form. Furthermore, such a situation would be
advantageous to the development of RA, where local
inflammation would be enhanced while the reduced plasma
DPPIV activity would be less effective at restricting the
bioactive peptides locally. Consequently, increased circulating
chemotactic and lymphokine/cytokine activities will lead to
inappropriate systemic activation. As increased CD26
expression is a marker strongly associated with extravasating
activated T cells, a role for DPPIV is implied [43,44]. It is
unlikely that the DPPIV activity per se is responsible for
clearing a path through connective tissue. It has been
demonstrated, however, that the DASH family member
seprase forms a complex with CD26 that is a prerequisite for
invasion and migration of fibroblasts through a collagenous
matrix [45]. T cells do not express seprase, but CD26 can
associate with other type II transmembrane prolyl serine
peptidases that may function in the invadopodia of activated
T cells [46]. The precise role of CD26 in invasion remains
enigmatic; the high expression of CD26 on transendothelial
migrating cells is a property of a previously determined CD4+
memory phenotype [43]. Extravasation is a continuous
process, and by inactivating chemokines as the migration
progesses, CD26 may keep the path at a surveillance level
rather than a full-blown immune invasion.
T cells expressing high levels of CD26, which are abundant
in the PB of RA patients, are believed to migrate into the
rheumatoid synovium to initiate local inflammation and tissue
destruction [47]. Within the SF, concentrations of IL-15, a
known inducer of CD26 on both T and NK cells, are high
[48]. Using the two monoclonal antibodies 1F7 and Ta1,
both of which recognize epitopes in the 100 amino acids
between residues 247 and 358 of DPPIV, Gerli et al. [49]
observed strong Ta1 positivity, but 1F7 negativity, on SF T
cells. The 1F7 antibody is able to cross-link CD26 and co-
stimulate TcR-driven stimulation, which is not the case for
Ta1. This difference in expression of the two epitopes
probably does not represent alternative forms of CD26, as
the epitopes are so close to each other. Other possibilities
include supramolecular associations that affect antibody
accessibility, or even cross-reactivity with unrelated
epitopes. In fact, 1F7 has already been shown to react
weakly with attractin [50].
Not only cross-reactivity but also differences in subcellular
localization of DPPIV (i.e. secretory endosomes or plasma
membrane) may have important consequences for T cell
reactivity and pre-secretion modification of bioactive peptides.
For example, total DPPIV activity within SF mononuclear cells
from RA patients is no different from those from osteoarthritic
(OA) patients, while the plasma membrane DPPIV activity is
significantly higher on cells from the OA patients [51].
Significantly lower DPPIV was found in SF of RA patients
compared with SF from OA patients or healthy donors
[34,52]. Within the synovium, synovial fibroblasts strongly
express DPPIV while the secreted activity is reduced [53],
similar to the relationship of T cell DPPIV to plasma DPPIV.
Nevertheless, as the joint fluid volume increases, the DPPIV
activity of RA synovial membrane decreases [54]. The
increased membrane DPPIV expression and reduced
secreted activity in the plasma/serum is now an accepted and
reproducible finding in RA, although not consistently
observed in the synovial fluid (Table 1). Despite the
inconsistency in reporting of differing DPPIV levels between
non-inflammatory and inflammatory synovial fluid, there is a
consistent, reproducible reduction in synovial fluid DPPIV
levels of a third to a half in comparison with circulating levels
(Table 1). Upon initiation of an inflammatory reaction within
the synovium, the reduced representation of DPPIV will lead
to a potentiation of the half-lives of immunoattractive and
enhancing peptides, including RANTES, SDF-1, vasoactive
intestinal peptide (VIP) and substance P (SP). The lower
synovial DPPIV activity in the context of higher circulating
levels in the periphery may contribute towards a gradient of
functional chemokine activity that will maintain attraction of
activated migrating immune cells into the synovium.
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The plasma DPPIV levels appear to be strongly reduced in
RA, and splitting patient samples into non-inflammatory and
inflammatory by C-reactive protein levels reveals the
reduction is predominantly observed in inflammatory RA [55].
Although we will describe later the therapeutic effects of
DPPIV inhibitors on RA progression, this does not, however,
necessarily imply a direct relationship between DPPIV activity
and inflammation. The development of an inflamed environ-
ment more properly represents a cascade involving multiple
heterogeneous cell types that may be maintained and
exacerbated by the activity of DPPIV. Nevertheless, in two
mouse models of inflammatory arthritis, the severity of joint
damage correlated directly with levels of SDF-1α where the
efficacy of this chemokine to attract T cells was directly and
negatively controlled by serum levels of DPPIV, and the joint-
infiltrating T cells had an increased expression of SDF-1α
receptor (CXCR4). As observed in human samples, plasma
levels of DPPIV were significantly reduced as the arthritis
developed [55]. The severity of the induced arthritis was
significantly increased in CD26-/- knockout mice, but in the
complete absence of CD26/DPPIV, few conclusions can be
drawn as to the relationship of systemic to synovial DPPIV
enzyme activity. Nevertheless, the more severe pathology
certainly supports a direct role for DPPIV in inactivating pro-
inflammatory substrates such as SDF-1α, particularly as the
mouse form lacks ADA binding activity. Due to the absence
of an alternatively spliced terminal exon, mice do not produce
a secreted form of attractin, but it has been suggested that
sequestering and inactivation of circulating chemokine
substrates is a function of the plasma secreted attractin
isoform in humans [56].
The activities of CD26 are not limited to DPPIV enzymatic
activity and its ADA binding capacity may be of importance.
The relative decrease in CD26+ T cells in SF, coupled with a
concomitant reduction in soluble DPPIV activity, relate
inversely to the concentration of free ADA, which is high in
RA patients [8,57]. As the methotrexate- and deoxyco-
formycin-based therapies act as anti-inflammatory agents by
increasing extracellular adenosine and blocking ADA,
respectively, the presence of high soluble ADA suggests a
pro-inflammatory environment independent of CD26. This
contention is questionable, however, because extracellular
ADA is not effective at overcoming high levels of adenosine
inhibiting T cells unless it is in complex with CD26. Because
the resident T cells appear to be CD26low, this suggests a
crucial role for strongly CD26+ activated T cells infiltrating
into the synovium from the periphery. This concept stresses
the kinetic nature of synovial inflammation where a single time
point assay may identify a synovial population of CD26low
‘spent’ T cells and miss a constant influx of CD26high
activated T cells driven by their high levels in the PB. A
mechanism driven in this manner would be consistent with
the systemic nature of RA, and suggests that any process
that results in long-term peripheral activation of T cells could
at some point lead to RA. The complex genetics of RA with
susceptibility loci on human chromosomes 1p13, 1p36,
5q31, 6p21.3 and 21q22.3 also point to multiple origins with
a uniform end process. It must be stressed that T cell driven
immune processes cannot be viewed in isolation as the
fibroblast-like synoviocytes express high levels of both CD26
and associated ADA isoform 1, which may maintain a pro-
inflammatory environment independent of the CD26low
T cells. A further issue is whether the presence of high ADA
will lead to maximal binding with CD26 because the affinity is
strong, with a KD of 65 nM [58]. The formation of ADA-CD26
complexes leads to an increase in ADA specific activity that
will directly reduce adenosine levels, reducing the efficacy of
methotrexate- and deoxycoformycin-based therapies.
Dipeptidyl peptidase II/quiescent cell proline
dipeptidase
Although sequence identities at nucleotide and tryptic
peptide-mass spectroscopic levels suggest that DPPII, QPP
and DPP7 are identical, there remain some differences in
substrate specifity and pH optimum criteria that prevent a
definitive conclusion of identity [9,59]. Nevertheless, until this
is resolved we will retain the terminology used in the original
reports. As both DPPII and QPP localize intracellularly, it is
unlikely that they will participate in the processing of extra-
cellular peptides, although it does not exclude the possibility
that they may modify peptides prior to secretion. The
presence of QPP in a post-Golgi vesicular compartment can
be inferred by its release as a secreted protein following
calcium mobilization. Initially identified in the human Jurkat
T cell line, expression profiling suggests it is widespread, with
strong representation in human blood, cervix, mammary
gland, ovary, uterus, kidney, lung, pancreas and skin,
suggesting an association with secretory processes related,
in particular, to the female reproductive system.
Although the physiological substrates for QPP remain
unknown, inhibition of QPP activity leads to an initiation of an
atypical apoptotic pathway in quiescent lymphocytes. No
significant sequence homology exists between CD26 and
QPP; it is the DPPIV-like enzymatic activity of DPPII/QPP that
classifies it as a DASH molecule. In contrast to the canonical
DPPIV, DPPII/QPP does not cleave neuropeptide Y (NPY) [3].
The relationship of DPPII/QPP/DPP7 activity to CD26-
related enzyme activity is complex in that DPPII activity
increases in the plasma of RA patients, while DPPIV
decreases [32]. This suggests that, overall, DASH activity
may be less critical than individual substrate specificity, which
may be influenced in large part by initial subcellular
localization rather than plasma levels. Significantly higher
DPPII activity was detected in SF [37,60] and in the synovial
membrane from RA patients than in OA cases, in which the
synovial membrane DPPII activity correlated positively with
the SF volume [54]. Although DPPII activity is low in
comparison to CD26, this suggests that DPPII is at least
associated with an inflammatory-mediated secretory process.
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Attractin
Attractin was initially identified as a serum protein with DPPIV
activity secreted by activated T cells [10]. Expression profiling
in several primary cells and cell lines revealed that, similar to
DPPII/QPP, its expression was not limited to T cells but
rather to all cells with strong secretory capacity [50]. A
membrane form was subsequently identified in humans and
its similarity with non-primate attractin, and the absence of
secreted attractin in non-primates, suggest that the
membrane-tethered form is the main functional entity [61].
Similar to CD26, attractin is a potent enhancer of recall
antigen-driven T-cell proliferation. There is no sequence
homology with CD26 and the classical serine protease
catalytic site is not present, which has led to debate about its
enzyme activity. Nevertheless, several studies have purified it
to apparent homogeneity with no contamination by CD26 but
with lower specific activity than that of native kidney-purified
DPPIV [10,11]. This raises the possibility that the DPPIV
activity of attractin may be secondary and that it has other
more specific substrate specificities yet to be identified,
similar to the NAALADases, which have both amino-terminal
DPPIV activity as well as a more pronounced carboxy-terminal
glutamate carboxylase activity. It has been suggested that the
secreted circulating form in humans may play a role in
systemic deactivation of chemotactic cytokines, ensuring that
the peptides are only active at the local site where they are
released. There are several instances where membrane
DPPIV activity does not correlate well with detected CD26. In
these cases, varying levels of other DASH molecules,
including attractin, may be responsible, which may be
indicated by alterations in DPPIV specific activity [28].
Alterations in the DPPIV levels in SF may represent an
increase in the presence of attractin. Certainly, analysis of
serum reveals an increase in attractin in RA patients with
erosive disease, which is not observed in individuals with
non-erosive RA or healthy individuals (B Guild, personal
communication) [62].
Seprase/fibroblast activation protein-α
Seprase probably plays a critical role in exacerbating joint
degeneration once it has been initiated. Expressed by
fibroblasts activated in a wound healing environment, seprase
has a strong gelatinase activity that aids breakdown of extra-
cellular matrix. Either alone or in complex with DPPIV/CD26
as a heterodimer, it localizes on invadopodia at the forefront
of extracellular matrix breakdown [45]. Once degeneration is
initiated in the synovium, seprase will be upregulated in
activated fibroblasts, where it will contribute to the
degenerative process. Unlike wound healing in general that
will be localized to a specific site and can thus be carefully
regulated without disturbing the overall immune homeostasis,
the presence of systemic activated T cells will lead to their
continuous influx into the inflamed synovium, maintaining the
inflammatory state. This will lead to a continuous activation of
synovial fibroblast seprase expression, a process further
maintained by the subsequent articular erosion.
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Other DASH molecules
The appreciation that DPPIV-like enzymatic activity may
reside in several molecules with differing specific activities
and representation requires a reinterpretation of a con-
siderable volume of data where DPPIV activity was measured
independent of antigenic reactivity or, conversely, where
CD26 antigenic activity but not DPPIV activity was measured.
This is complicated further by a lack of understanding of the
breadth of substrate and inhibitor specificities for the DASH
family. This is illustrated well by the CD26-knockout mouse
that still retains a circulating DPPIV activity almost 13% that
of controls despite a complete absence of immunologically
detectable CD26 [63]. Furthermore, the residual activity in
the CD26 knockouts could not be inhibited by the DPPIV
inhibitor valine-pyrrolidide. Accordingly, multifactorial analysis
of inhibitor panels and antibody-binding specificities may
prove to be a useful technique for weighting the contribution
of individual DASH family proteins to DPPIV-mediated
degradation of bioactive peptides.
The DASH family substrates: enzymatic
regulation and their relationship with
rheumatoid arthritis
The immune system receives input not only from the cells and
messengers considered to be part of the classic immune
network, but is clearly also influenced by neuroendocrine and
reproductive signals. Consequently, the pathogenesis of the
chronic disabling inflammatory diseases, of which RA is one,
must take into account these extra-immune influences. By the
same token, despite the understanding that multiple mediator
abnormalities may contribute to RA development [64,65], it is
difficult to assess whether effects in vivo related to a
neuroendocrine peptide are direct upon the immune cell, or
indirect through creating an environment that modulates
immune activity. For example, malnutrition leads to an
immunosuppression that was not well understood until the
discovery that adipocyte-derived leptin levels fall in the fasting
condition or during inflammation, and T cell responses
independent of the nutritional state can be restored by
administration of leptin, which binds directly to receptors on
T cells [66]. In several instances, there is clear evidence for
neuroendocrine receptors on immune cells, and many of the
ligands for these receptors have been identified as substrates
for DPPIV activity. It is already well established that DPPIV
cleavage can have powerful effects upon cytokine and
chemokine activity. In the sections below, we will examine
how the increased DPPIV activity associated with activated T
cells may exacerbate the systemic inflammatory reaction
characteristic of RA by modifying neuropeptide, cytokine and
chemokine functionalities.
Neuropeptides
To date, neuropeptides that have been shown to directly
modulate immune function through expressed receptors
include SP, the pancreatic polypeptide family (including
NPY), calcitonin gene-related peptide (CGRP), VIP and
gastrin-releasing peptide (GRP). Remarkably, not only do the
levels of several of these neuroendocrine peptides undergo
distinct alterations in active RA, but all have been identified as
substrates for DPPIV activity where the highly specific
clipping of the amino-terminal dipeptide with a penultimate
proline may have profound effects upon receptor agonism
and downstream functionality (Fig. 1). The presence of higher
levels of surface DPPIV on systemic PB T cells will probably
not have a significant effect upon the paracrine activities of
these immune-activating neuropeptides, but the relative
decrease of DPPIV/CD26 on the surface of SF-localized
T cells may lead to a potentiation of the neuropeptide half-life,
exacerbating the local inflammation.
Substance P
SP is an undecapeptide belonging, together with neurokinins
A and B, to the tachykinin family. It is released by sensory
neurons, fibroblasts, macrophages and fibroblast-like synovio-
cytes. Although SP can bind to at least three membrane
G protein-coupled receptors (the neurokinins NK1, NK2,
NK3), its main target appears to be the NK1 receptor. The
levels of SP in SF are high in RA [67], and downstream
signaling leads to varying consequences depending upon the
target cells. Mononuclear phagocytes respond with increased
prostaglandin E2 and IL-1β, TNF-α and IL-6 secretion while
mast cells respond by degranulation [68]. Rheumatoid
synoviocyte proliferation is enhanced, and fibroblast-like
synoviocytes release collagenases, IFN-γ, TNF-α, IL-1β, and
oxygen radicals and upregulate surface adhesion proteins
such as vascular cell adhesion molecule 1 in response to SP
[69]. Intra-articular injection of IL-1 or TNF-α increases SP
concentration in the SF and leads to cartilage degradation,
while transforming growth factor (TGF)-β was shown to
induce SP production in synovial fibroblasts [70]. In this
respect, RA fibroblast SP release was more sensitive to TGF-
β induction than were fibroblasts from OA subjects [69].
In responding to physiological levels of SP, leukocytes from
patients with RA strongly upregulate release of IL-1β, TNF-α
and IL-6 in contrast to a much lesser effect upon leukocytes
from non-inflammatory OA [71]. This effect appears to be
related to an increased representation of SP receptors and is
supported by reports that pre-incubation of PB leukocytes
from RA patients showed a stronger expression of T cell
activation markers than did cells from controls [72], while SP
stimulates T cell proliferation in RA patients more efficiently
than in controls [73].
The biological effects of SP in vitro are mediated as
effectively by the carboxy 4-11 fragment as by the full-length
peptide, implying that DPPIV-mediated cleavage of an amino-
terminal dipeptide will not affect receptor specificity or alter
agonist-mediated downstream signaling. Nevertheless, the
amino-terminal penultimate proline is resistant to cleavage by
other aminopeptidases, lending protection against degradation.
Consequently, removal of the amino-terminal dipeptide by
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DPPIV significantly shortens the in vivo biological half-life of
SP [74].
The pancreatic polypeptide family
The pancreatic polypeptide family comprises NPY, peptide
YY, and pancreatic polypeptide. NPY has pleiotropic
activities across the endocrine, nervous and immune systems,
signaling via at least five (Y1 to Y5) receptor subtypes.
Hydrolytic processing of NPY by DPPIV changes its resulting
receptor preference, converting it functionally from a Y1 to a
Y2/Y5 agonist. Although NPY is very efficiently cleaved by
DPPIV, it is highly resistant to hydrolytic attack by DPPII,
another DASH member dysregulated in RA [3]. Both DPPIV
and NPY are co-expressed not only in circulating immune
cells but also in the vascular endothelium, supporting a role
for DPPIV in the regulation of systemic NPY [75]. NPY acts,
among other functions, as a chemoattractant and activator of
mononuclear cells [76]. Together with SP, NPY induces
phagocytosis and activation of macrophages as well as
leukocyte production of TNF-α and other pro-inflammatory
cytokines. Mononuclear blood cells from RA patients are
more responsive to NPY than are similar cells from non-
inflammatory OA patients, with strong increased secretion of
IL-1β, TNF-α and IL-6, suggesting a change in receptor
density as noted above for SP receptors.
Simultaneous application of TNF-α and IFN-γ to endothelial
cells causes an increase in NPY, upregulation of the Y5
receptor, and complete loss of the Y2 receptor, together with
an upregulation of DPPIV activity. Because the DPPIV-
cleaved NPY binds effectively to the Y5 receptor, an
autocrine loop is created [77] that might exacerbate activity
of already activated RA T cells. These observations fit well
with studies demonstrating NPY-associated chemoattractant
and adhesion-inducing properties for leukocytes [78].
Certainly, increased levels of NPY are observed in SF of
patients with RA [79]. Evidence for regulation of local
inflammation is provided by the report that locally applied
NPY potentiated, while NPY Y1 receptor antagonist
abolished, concanavalin A-induced paw edema in rat [80]. In
contrast, excessive stimulation of peritoneal macrophages by
NPY suppresses TNF-α, and a similar effect has been noted
upon IL-2 release by mouse leukocytes [71]. As mentioned
above, however, results from mice must be treated cautiously
because DPPIV/CD26 is not an activation antigen and does
not bind ADA in them.
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Figure 1
Contribution of dipeptidyl peptidase IV-sensitive neuropeptides to the control of inflammation in rheumatoid arthritis. Gray arrows indicate release
of indicated mediator; black arrows indicate stimulation of indicated cell function; dashed lines indicate abrogation of cell function and/or release of
indicated mediator. ‘Endogenous opioids’ include enkephalins, endorphins, dynorphin and endomorphin. CGRP, calcitonin gene-related peptide; 
IL, interleukin; NPY, neuropeptide Y; PGE2, prostaglandin E2; RO2
–, reactive oxygen species; SP, substance P; TNF, tumor necrosis factor; 
VIP, vasoactive intestinal peptide.262
Calcitonin gene related protein
Compared to the other neuropeptides discussed, less is
known about the immune effects of CGRP and the
consequences of its proteolysis by DPPIV. This is in part due
to CGRP functioning in the context of SP, with which it is
usually colocalized and coreleased, providing an additive or
synergistic effect. As for SP, increased concentrations of
CGRP are observed in SF of RA patients [81], and it similarly
induces high levels of IL-1β, TNF-α and IL-6 from RA PB
leukocytes [71]. There is one report, however, of an anti-
inflammatory CGRP effect leading to decreased IL-2
production [82].
Vasoactive intestinal peptide
VIP is predominantly viewed as an anti-inflammatory and anti-
autoimmune mediator, executing its role mostly via down-
regulation of pro-inflammatory mediators; in RA, this is
observed for chemokines and TNF-α derived from isolated
synovial cells [83]. Consistent with these observations, VIP
administration decreased the severity of experimental arthritis
in rodents [84]. Slightly elevated concentrations of VIP were
observed in SF of RA patients compared to OA samples
[81], suggesting an attempt by the immune system to down-
regulate a cascading immune reaction. Nevertheless, at the
systemic level, VIP probably can also induce strong
production of some pro-inflammatory cytokines, including
TNF-α, IL-6 and IL-1β, by RA PB cells at significantly higher
levels than the release associated with noninflammatory cells
from OA patients [71]. The balance of stimulatory and
inhibitory effects of VIP and the effects of DPPIV activity is
not a situation that can be duplicated in vitro, but rather
represents the complexity of trying to model local
environments where inflammation is being driven by an influx
of activated cells from the systemic circulation.
Bombesin/gastrin-releasing peptide
Among its other functions, bombesin/GRP is believed to act
as a tissue-specific paracrine growth factor that promotes
proliferation of chondrocytes and stimulates antibody-
dependent cellular cytotoxicity and NK cell activity [85,86]. In
contrast with healthy controls, most RA patients, particularly
those with an early arthritis, displayed measurable
concentrations of GRP in the SF where the GRP
concentration correlates with the number of SF leukocytes
[67].
Cytokines
Cytokines are secreted by activated immune cells, mainly
T cells and macrophages, as well as by other cell types such
as fibroblasts. They have been found in synovial membrane
and fluid in RA, psoriatic arthritis and OA, with quantitative
differences observed dependent both upon disease type and
severity [87-89].
Levels of TNF-α, IL-1 and IL-6 in RA SF and synovial tissues
from RA patients are high and significantly higher than those
in samples from controls and OA patients [90]. The ability of
DPPIV to cleave these lymphokines is inversely correlated
with the chain length [91]. It appears that DPPIV can cleave
carboxy-shortened TNF-α, IL-1 and IL-6 but not the full-length
mature peptides. The significance of this is difficult to
interpret because the effects here of DPPIV would be anti-
inflammatory. Further, the resistance to cleavage of full-length
peptide has only been observed with CD26, and does not
exclude cleavage by other DASH members, or their
synergistic activity, or even an extracellular protein-assisted
conformational change that would open the amino-terminal of
the full-length protein to cleavage. In support of a mechanism
more complex than simple CD26-mediated cleavage in vitro,
full-length TNF-α undergoes a DPPIV-like cleavage in U937
human monocyte-like cells, and an identical activity was
identified in both primary macrophages and monocytes [92].
Given the critical role ascribed to TNF-α in RA-associated
inflammation [93], and that this lymphokine can itself induce
fibroblasts and monocytes to produce downstream DPPIV
substrates, including RANTES, macrophage inflammatory
protein (MIP)-1 and IFN-γ inducible protein-10 (IP-10) [94-
97], it is clear that DPPIV analysis should be global and not
focused only on CD26 (Fig. 2).
TNF-α induces IL-1β secretion by macrophages and mono-
cytes, leading to activation of synoviocytes, T and B cells and
increased production of structural protein degrading enzymes
in the RA joint environment. A positive correlation was found
between IL-6 and SP levels as well as between IL-6 and the
cell count in SF of patients with RA. In contrast with SP, VIP
and CGRP, an elevated IL-6 concentration was detectable
also in blood plasma of RA patients [81]. Because DPPIV
activity should be inhibitory for most of these processes, the
reduced DPPIV activity observed within the enflamed
synovium would lead to longer biological half-lives for all
these lymphokines, with the consequent maintenance of the
activated state.
Chemokines
Chemokines constitute a large superfamily of paracrine/
autocrine ‘chemotactic cytokines’ that bind to G protein-
coupled seven-span transmembrane receptors and control
leukocyte migration and homing as well as maturation and
release of inflammatory mediators. They are classified into
four subfamilies (CXC, CC, C, and CX3C) based on the
number and spacing of the first two or four cysteine residues.
The pro-inflammatory cytokines such as TNF-α and IL-1β,
which are believed to play a critical role in the pathogenesis
of RA, have been shown to upregulate a number of
chemokines from several cell types within the synovium.
Although the relative contribution made by individual
chemokines is not yet clear, a growing number of reports
indicate that RANTES (CC ligand (CCL)5), MIP-1β (CCL4),
monokine induced by interferon-γ (Mig; CXC ligand
(CXCL)9), IP-10 (CXCL10) and SDF-1α (CXCL12) actively
participate in RA pathogenesis and have been shown to be
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substrates for DPPIV activity [94-96,98-101]. Amino-terminal
processing of these molecules modifies, both quantitatively
and qualitatively, their receptor preference and consequent
functional properties.
In the RA synovial environment, Mig was found mainly in
monocytic cells, whereas RANTES is expressed
predominantly by CD3+ lymphocytes. Mig and IP-10, both
ligands for the CXC receptor (CXCR)3, are attractants for
lymphocytes mediating Th1-type responses in the RA
enflamed joint. Their presence and expression create a
gradient from the joint to the blood favoring Th1 cell migration
into the tissue. In OA cases, the gradient appears to be
generated in the opposite direction [102,103]. Memory
CD4+ T cells, the major cell population present in the
synovium infiltrate, strongly express the chemokine receptors
CXCR3, CXCR4, CXCR6 and CCR5, which all bind pro-
inflammatory chemokines. SDF-1 is important for retaining
cells in the inflamed joint, and its receptor (CXCR4) is
strongly upregulated in the synovium by IL-15 and TGF-β,
both of which are highly expressed in SF [95]. Production of
SDF-1 by rheumatoid synovial fibroblasts is probably critical
in maintaining the recruitment of CXCR4 expressing T cells
from the periphery to inflamed synovium [104,105]. Strong
evidence that DPPIV-mediated inactivation of SDF-1 is an
integral part of SDF-1 signaling and regulation of T cell
attraction is provided by the report that CXCR4 and CD26
form a tight molecular complex and are internalized together
following ligation and co-precipitate together in antibody-
based pulldown assays [106]. Confirmation of these
inferential findings has been demonstrated in mouse articular
inflammatory models where DPPIV proteolysis of SDF-1α in
vivo was shown to directly regulate T cell recruitment to the
inflamed regions [55].
Robinson  et al. [96] demonstrated elevated levels of
RANTES, another DPPIV substrate, in PB, SF, and synovial
tissues of RA patients. Expression of RANTES was un-
detectable in OA synovia, where inflammatory lymphocyte
infiltration is not observed. Binding of RANTES to the chemo-
kine receptors CC receptor (CCR)1, CCR3 and CCR5 leads
to selective recruitment of T cells and monocytes into the
synovium [94]. CCR3 and CCR5 receptors are upregulated
on RA-derived cells, both in the periphery and in the inflamed
synovium, rendering the cells more sensitive to local RANTES
attractive gradients. Perhaps helping to exacerbate the initial
inflammation, the receptor density increases as the SF
leukocyte count increases. CCR5 expression is detected on
the majority of cell types in the synovial environment,
including macrophages, fibroblasts, vascular smooth muscle
cells and perivascular lymphocytes [99]. Its expression on
peripheral and synovial CD4+ cells in RA patients is further
upregulated by IL-15, a pro-inflammatory cytokine [48].
RANTES is not the only DPPIV substrate elevated in RA;
MIP-1α is also increased and also binds to CCR5 [97,98].
Examination of CCR5 antagonists as a therapeutic modality
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Figure 2
Contribution of dipeptidyl peptidase IV-sensitive cytokines to the control of inflammation in rheumatoid arthritis. Gray arrows indicate release of
indicated mediator; black arrows indicate stimulation of indicated cell function; dashed lines indicate abrogation of cell function and/or release of
indicated mediator. CCR, CC receptor; IL, interleukin; IP-10, IFN-γ inducible protein-10; Mig, monokine induced by interferon-γ; MIP, macrophage
inflammatory protein; RANTES, regulated upon activation normal T-cell expressed and secreted; SDF, stromal cell-derived factor; TNF, tumor
necrosis factor; VCAM-1, vascular adhesion molecule-1 (CD106).264
have been shown to inhibit collagen-induced arthritis in mice,
an effect ascribed to interference with T-cell migration [107].
Following cleavage of RANTES by DPPIV, loss of the amino-
terminal dipeptide did not have a profound effect upon T cell
chemotaxis, but resulted in a loss of monocyte attraction
[108]. This may represent a shift in receptor expression on
monocytes as there is evidence of an affinity shift for
RANTES from CCR1 to CCR5 after DPPIV cleavage. In
addition, these results examined only the effect of CD26
upon RANTES without considering other DASH enzyme
activities. Analysis using MALDI-TOF of full-length RANTES
following incubation with either attractin or CD26 reveals that
attractin cleaves only the amino-terminal dipeptide while
CD26 may then release a further dipeptide from the amino
terminus consisting of amino acids Tyr3 and Ser4, and will
similarly release the same dipeptide from synthetic
(3-68)RANTES, a further digestion that may also influence
receptor preference [56].
DPPIV enzymatic activity inhibitors in
rheumatoid arthritis
Therapeutic options for modifying DPPIV activity in RA would,
at first glance, seem facilitated by the recent advances in
designing a large panel of inhibitors to block degradation of
glucagon-like peptide 1 (GLP1), another DPPIV substrate
that plays a critical role in controlling glucose metabolism
[109]. Nevertheless, there are several concerns. DPPIV levels
are low to normal in the inflamed synovium, with the
consequence that chemokines such as SDF-1 and RANTES
will have enhanced longevity. Administration of systemic
DPPIV inhibitors will serve only to enhance the biological half-
life, potentiating influx of activated T cells from the periphery.
Conversely, the high level of DPPIV/CD26 on activated
systemic T cells is essential for efficient transendothelial
migration [44], and blocking of DPPIV activity may be critical
for blocking migration into the synovium. The blocking of
migration and enhanced degradation of chemokines will need
to be carefully balanced, and experimental animal models may
be limited for this purpose for several reasons. First, it
remains to be shown that experimentally induced mouse
arthritis really represents the systemic infiltration process
seen in the human disease as opposed to a local
inflammation that just happens to have been induced in the
joint. Second, the role and functions of CD26 in the rodent
are quite different to those in humans. Third, it is clear that
members of the DASH family are not uniformly sensitive to
inhibitors, each member expressing a unique spectrum of
inhibition responses to a panel of DPPIV-specific inhibitors.
Finally, as alluded to above, there are several peptide
modulators of metabolism that are substrates for DPPIV
activity, and systemic administration will affect these
processes as well as immune processes.
The importance of these complicating factors relative to the
desired reaction to be controlled cannot be predicted, and
needs to be experimentally determined. Certainly, T cell
proliferation and TNF-α production in vitro can be abrogated
by DPPIV inhibitors [110]. Inhibition of DPPIV suppressed
both cellular CD26 expression, serum DPPIV activity and
prolonged allograft survival [31,111]. Similar DPPIV inhibition
in vivo led to an increase of immunosuppressive cytokine
TGF-β1 in plasma, but did not cause a nonspecific general
immunosuppression. Furthermore, DPPIV inhibitors have
been shown to suppress T lymphocyte subpopulation
migration into the inflamed tissue, as well as suppressing
T cell DNA synthesis, and TNF-α, IL-1 and antibody
production, all processes that may need to be controlled in
RA [112]. Conversely, in some monocyte-derived cell
populations, DPPIV enzymatic activity inhibitors may stimulate
production of TNF-α [113].
Despite the compound and model-specific effects, there is
increasing evidence that systemically distributed DPPIV
inhibitors might have potent, dose-dependent anti-arthritic
effects associated with down-regulation of a number of pro-
inflammatory parameters both in vitro and  in vivo in
experimental animals [114-117]. Reinforcing the notion that
systemic blocking of circulating T cell-associated DPPIV will
be useful while synovial blocking might be counterproductive,
DPPIV inhibitors were shown to increase the effect of SP on
mitogen-induced proliferation of T cells, IL-2 production by
T cells, immunoglobulin synthesis by B cells and TNF-α as
well as other cytokine production by monocytes [68,118,
119]. Similarly, the pro-inflammatory effects of NPY in
concanavalin A-induced paw edema in rat was potentiated by
co-application of a DPPIV inhibitor [80].
The potential to target systemic DPPIV and limit activity in the
extracellular fluids would be desired pharmacologically, as
would targeting of inhibitors to give broad spectrum inhibition
of DASH family molecules. Ideally, preservation of DPPIV
activity for peptides involved in metabolism and neuro-
physiology would be maintained. Such a trade-off may be
accomplished not by complete broad inhibition of DPPIV
activity, but simply by administration of inhibitor cocktails that
would bring systemic cell-associated DPPIV activities within
the low to normal range.
Conclusion
The chronic systemic inflammatory reaction characteristic of
RA results in breakdown of cartilage and erosion of proximal
bone. The initial insult that leads to development of
autoreactive T cells remains enigmatic, but there can be no
doubt that circulating activated T cells extravasate into the
synovium where they release or express various factors that
potentiate resorption of both cartilage and bone. The damaged
synovial cells themselves release cellular components that
mimic wound healing, leading to the further recruitment of
immune cells. The predisposing factors, including genetic
associations and possible initiating peptides, are not
discussed here. This review instead addresses the involve-
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ment of DASH enzymatic activity in every step of the post-
insult process, from T cell activation to extravasation, and
from cartilage breakdown to the release of chemokines and
cytokines that attract new T cells and monocytes, thereby
increasing the inflammatory response and exacerbating
degeneration. Some of the proposed interactions and
mechanisms are outlined in Fig. 3.
The DASH family members, predominantly CD26 and
attractin, are rapidly upregulated on T cell activation.
Following increased expression on the T cell surface, DPPIV
plays a critical role in allowing the activated T cells to
extravasate into the extracellular space. Once in the vicinity of
the synovium, the DPPIV activity would be able to initiate
amino-terminal degradation of the increased levels of pro-
inflammatory neuropeptides, cytokines and chemokines that
are present and are substrates for such activity. This
degradation might be effective in down-regulating inflam-
mation were it not for the remarkable observation that DPPIV
activity in the RA inflamed synovium is low to normal and
does not reflect the higher levels in the peripheral circulation,
which themselves are lower than normal. The lower level of
secreted DPPIV in RA is matched by a reciprocal increase in
T cell membrane expression (Table 1), which leads to an
increase in the extravasation potential of a T cell while
simultaneously extending the chemoattractive capacity of
DPPIV-sensitive RANTES and SDF-1α. Why is secreted
CD26 low in the synovium? Ligation and cross-linking of
CD26 leads to its internalization, and because CD26 can
bind collagen, there exists a strong possibility that synovio-
cytes internalize CD26 cross-linked by fragments from the
degenerating synovial lining. Reduction of the membrane
levels in this way would also reduce the amount available for
cleavage and release. Proteoglycans released into the
synovial fluid by articular degeneration may contribute further
to chemoattraction because their presence is necessary for
efficient presentation of basic-charged chemokines such as
RANTES and SDF-1α to their respective receptors [120,
121]. The binding of chemokines by the proteoglycan
fragments may also shield them from DPPIV proteolysis.
Available online http://arthritis-research.com/content/7/6/253
Figure 3
Overview of regulation of dipeptidyl peptidase (DPP)IV enzymatic activity and its substrates in rheumatoid arthritis-related inflammation. Gray
arrows indicate modification of mediator receptor preference by proteolytic modification; black arrows indicate stimulation of indicated mediator or
enzymatic activity; dashed lines indicate termination of indicated mediator function by proteolytic degradation; dotted lines indicate down-regulation
of indicated receptor. Biologically active peptides are shown in regular font and receptors are shown in italics. See the text for references. CCR,
CC receptor; CGRP, calcitonin gene-related peptide; CXCR, CXC receptor; IL, interleukin; MIP, macrophage inflammatory protein; NK, natural
killer; NPY, neuropeptide Y; NPYR, neuropeptide Y receptor; SDF, stromal cell-derived factor; SP, substance P; TNF, tumor necrosis factor; VIP,
vasoactive intestinal peptide.266
Therapeutic options include the systemic administration of
DPPIV inhibitors together with TNF-α antagonists such as
etanercept, adalimumab, and infliximab. The synergistic
activity upon TNF-α and its downstream DPPIV-sensitive
substrates would allow administration of lower doses of the
TNF-α antagonists, thus reducing the incidence of adverse
side effects [122]. Other potentially more innovative but
complex approaches would include the systemic
administration of DPPIV inhibitors to reduce circulating
activated T cell activity with direct injection of recombinant
DPPIV into the inflamed synovium to inactivate chemokines
and reduce T cell and monocyte recruitment. Although
collagen-induced arthritis in rodent models is of limited
usefulness for modeling systemic RA processes, it would
nevertheless be useful for testing of such novel approaches
to the control of local inflammation in the synovium.
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